Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
UBS
Novartis
Mallinckrodt
Medtronic
Covington
Johnson and Johnson
Colorcon
QuintilesIMS
McKinsey

Generated: February 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,211,253

« Back to Dashboard

Which drugs does patent 9,211,253 protect, and when does it expire?

Patent 9,211,253 protects NARCAN and is included in one NDA.

This patent has fourteen patent family members in eleven countries.
Summary for Patent: 9,211,253
Title:Nasal drug products and methods of their use
Abstract: Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided.
Inventor(s): Crystal; Roger (London, GB), Weiss; Michael Brenner (New York, NY)
Assignee: Lightlake Therapeutics Inc. (New York, NY)
Application Number:14/659,472
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Delivery; Device; Use;

Drugs Protected by US Patent 9,211,253

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Adapt NARCAN naloxone hydrochloride SPRAY, METERED;NASAL 208411-001 Nov 18, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,211,253

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,468,747 Nasal drug products and methods of their use ➤ Try a Free Trial
9,629,965 Nasal drug products and methods of their use ➤ Try a Free Trial
9,707,226 Nasal drug products and methods of their use ➤ Try a Free Trial
9,775,838 Nasal drug products and methods of their use ➤ Try a Free Trial
9,480,644 Nasal drug products and methods of their use ➤ Try a Free Trial
9,561,177 Nasal drug products and methods of their use ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,211,253

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Singapore 11201607281P ➤ Try a Free Trial
European Patent Office 3116478 ➤ Try a Free Trial
Spain 2631504 ➤ Try a Free Trial
United Kingdom 201616616 ➤ Try a Free Trial
United Kingdom 2538682 ➤ Try a Free Trial
Japan 2017508800 ➤ Try a Free Trial
Mexico 2016011902 ➤ Try a Free Trial
China 106163499 ➤ Try a Free Trial
Germany 112015001251 ➤ Try a Free Trial
Canada 2942611 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Baxter
Healthtrust
Mallinckrodt
AstraZeneca
Argus Health
McKesson
Cerilliant
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot